What is Onivyde?
Onivyde (nal-IRI) is a chemotherapy drug used to treat pancreatic cancer [1]. It is a liposomal formulation of irinotecan, a topoisomerase I inhibitor [1].
How is Onivyde Administered?
Onivyde is given intravenously (IV) by a healthcare professional [1].
What Other Treatments Are Used with Onivyde?
Onivyde is typically used in combination with other chemotherapy agents, such as fluorouracil and leucovorin, for adults with previously treated metastatic pancreatic adenocarcinoma [1].
What Discounts Are Available for Onivyde?
Information regarding specific discounts for Onivyde is not publicly detailed. However, patients may be eligible for financial assistance programs offered by the manufacturer or through independent foundations [1]. These programs can help reduce out-of-pocket costs for eligible individuals.
What Should Patients Consider Regarding Onivyde Costs?
Patients should discuss the potential costs of Onivyde treatment with their healthcare provider and their insurance company. They can also inquire about patient assistance programs that may be available to help manage medication expenses.
How Does Onivyde Work?
Onivyde works by delivering irinotecan to cancer cells more effectively. The liposomal encapsulation protects the drug from rapid metabolism and allows for a sustained release, which can improve its therapeutic effect [1].
What are the Potential Side Effects of Onivyde?
Common side effects of Onivyde can include diarrhea, fatigue, nausea, vomiting, decreased appetite, and stomatitis [1]. Serious side effects can occur, and patients should report any concerns to their doctor.
How Long Does Onivyde Treatment Last?
The duration of Onivyde treatment depends on the individual patient's response to the therapy and their doctor's recommendations. It is part of a treatment plan for metastatic pancreatic cancer [1].
Who Manufactures Onivyde?
Ipsen Biopharmaceuticals is the manufacturer of Onivyde [1].
Sources:
[1] https://www.drugpatentwatch.com/drugs/onivyde